Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budesonide nebulizer for children with community-acquired pneumonia
IRCT20240204060891N1Phase 3Completed
- Sponsor
- Shahrekord University of Medical Sciences
- Start
- Mar 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of budesonide in community-acquired pneumonia (CAP) (2 arms), sponsored by Shahrekord University of Medical Sciences. Primary endpoints: Duration of hospitalization, Duration of fever and 9 more. Started Mar 2024; status: completed.
02
Drugs
budesonide
03
Conditions
community-acquired pneumonia (CAP)
Beyond the preview
Go deeper on IRCT20240204060891N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240204060891N1.